Filing Details
- Accession Number:
- 0001599901-24-000197
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-13 18:08:39
- Reporting Period:
- 2024-12-11
- Accepted Time:
- 2024-12-13 18:08:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1599901 | Avidity Biosciences Inc. | RNA | Pharmaceutical Preparations (2834) | 461336960 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1841990 | Michael W. Flanagan | C/O Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego CA 92121 | Csto | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-12-11 | 24,000 | $22.47 | 109,389 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-12-11 | 24,000 | $35.77 | 85,389 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-11 | 24,000 | $0.00 | 24,000 | $22.47 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
86,000 | 2033-01-19 | No | 4 | M | Direct |
Footnotes
- The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person.
- This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.37 to $36.46. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.